![]() In early March, Oppenheimer analysts reworked their estimates model to account for a recent $285 million convertible share offering and, you guessed it, another key acquisition. ![]() DoseMe is the developer of DoseMeRx, an advanced precision dosing tool to help physicians and pharmacists accurately dose patients’ high-risk parenteral medications based on individual needs, resulting in significant improvements to mortality, risk, and patient outcomes.Īlready available in over 100 hospitals and infusion providers worldwide, DoseMeRx’s precision dosing capabilities will now be combined with TRHC’s proprietary Medication Risk Mitigation (MRM) technologies in order to enhance and accelerate medication safety solutions available in the hospital setting. In December, Tabula Rasa announced an agreement to acquire Brisbane, Australia-based DoseMe. The integration is expected to be complete by Q4'19 and create a recurring revenue SaaS fee as well as a consulting fee for Tabula Rasa. ![]() The company also recently announced an important API integration with fellow healthcare IT company AthenaHealth, formerly public under the symbol ATHN and taken private in February by Elliot Management and Veritas Capital who teamed up to buy ATHN for over $5.5 billion in cash, or $135 per share.Īthenahealth serves over 100 million patients through provider networks and will embed Tabula Rasa platforms in care and pharmacy settings. This technology strategy, referred to as TRHC 2.0, is designed to harness the power of TRHC’s core technologies, MedWise™ and EireneRx®, and to leverage other technologies brought into the company through acquisition, like SinfoniaRx’s RxCompanion®, and the recent Mediture and eClusive technologies for electronic health records and health plan management. (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, today announced its strategy to integrate and open its various technologies, facilitating seamless interoperability and access to vast data resources for its clients. 07, 2018 (GLOBE NEWSWIRE) - Tabula Rasa HealthCare, Inc. Through accretive acquisitions and continued research and development, TRHC’s technology innovations and growing data lake provide a data continuum for clients enhancing the care of patients across the U.S. In September, the company announced the creation of TRHC 2.0 for "Innovative Integrations, Interoperability and Advanced Healthcare Analytics." From the 9/7/18 press release. One of the most exciting innovations for Tabula Rasa is their development of a complete medical records and IT solutions suite that integrates with other providers. New Partnerships, Acquisitions, and Innovations Full-year 2019 consensus moved back up 10% from $0.70 to $0.77 and next year moved from $1.07 to $1.19. And this after analysts held loftier expectations about 2019 growth as recently as last October when the consensus was for EPS of over $1.10.īut the reason the stock became a Zacks #1 Rank again is due to upward EPS revisions that came in after the company's Q4 report on Feb 28 where management raised revenue guidance. Part of the pessimism is that while the company became profitable last year, it is expected to show no EPS growth this year and deliver a repeat of $0.77, giving it a P/E multiple of over 70X. What you are seeing is 12-month forward sales estimates (the green line) rising from $210 million at the start of Q3 2018 to over $325 million projected into 2020, while price has dropped from $90 to $55. This view highlights projected sales growth in the face of the recent valuation haircut. ![]() Below is a snapshot I took last month when I bought TRHC shares for the Zacks Healthcare Innovators portfolio. Tabula Rasa is expected to grow sales 40% this year to $285 million. And their innovative use of artificial intelligence technologies and cross-provider integrations for doctors and pharmacies to cross-reference prescription complications is becoming more important in an aging population taking more medicines. The company's cloud-based software applications, including platforms EireneRx and MedWise Advisor, deliver control and certainty to payers, providers and other healthcare organizations. Tabula Rasa HealthCareis a $1.2 billion medical IT firm focused on patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. In addition, Zacks Equity Research provides analysis on Roku ROKU and Netflix NFLX. Chicago, IL – – Zacks Equity Research highlights Tabula Rasa HealthCare TRHC as the Bull of the Day and Tesla TSLA as the Bear of the Day.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |